Evantuxumab: Pioneering the Treatment of EGFRex20ins Mutations in Lung Cancer

In the quest to overcome drug resistance caused by EGFR gene mutations, pharmaceutical companies worldwide are making concerted efforts. Johnson & Johnson has turned its attention to EGFR/c-Met bispecific antibodies, targeting two key drivers of lung cancer mutations. This approach holds promise for effectively suppressing lung cancer and addressing drug resistance. One of the most significant EGFR mutations, EGFRex20ins (EGFR exon 20 insertion), has become the focus of Johnson & Johnson's efforts. They have designed the first-ever EGFR/c-Met bispecific antibody, evantuxumab, targeting the EGFRex20ins mutation. In May 2021, evantuxumab obtained accelerated FDA approval based on Phase 1b clinical data.

Evantuxumab: A Crucial Step Towards Solid Tumor Treatment:
Evantuxumab represents a crucial step for Johnson & Johnson's entry into the solid tumor field. It is also the world's first bispecific antibody approved for the treatment of solid tumors. Currently, evantuxumab is used as a second-line therapy for patients with EGFRex20ins mutations. However, Johnson & Johnson aims to expand its usage to first-line therapy, thereby benefitting a larger patient population.

Positive Results in First-Line Combination Therapy:
On October 21st, positive results were announced for evantuxumab in combination with chemotherapy as a first-line treatment for advanced or metastatic NSCLC patients with EGFRex20ins mutations. Compared to chemotherapy alone, the combination therapy reduced the risk of disease progression or death by 60%. The progression-free survival (PFS) for the combination therapy and chemotherapy groups were 11.4 months and 6.7 months, respectively. The overall response rate (ORR) was 73% for the combination therapy and 47% for chemotherapy alone, highlighting the significant advantages of the combination therapy.

Promising Results in Combination with Lazertinib:
Simultaneously, positive results were also observed for evantuxumab in combination with lazertinib as a first-line treatment for locally advanced or metastatic NSCLC patients with Ex19del or L858R mutations. The combination therapy reduced the risk of disease progression or death by 30% compared to osimertinib, demonstrating a favorable trend in overall survival (OS) in the interim analysis.

Combination Therapies for Osimertinib-Resistant NSCLC:
Evantuxumab in combination with chemotherapy or evantuxumab in combination with lazertinib and chemotherapy demonstrated risk reductions of 56% and 52%, respectively, for disease progression or death in patients with locally advanced or metastatic NSCLC who had developed resistance to osimertinib following EGFRex19del or L858R substitutions.

The Clinical Efficacy of Evantuxumab:
The various clinical trial results demonstrate the robust efficacy of evantuxumab and its potential for first-line therapy. Its future prospects in the field of lung cancer are promising.

Domestic Progress:
In terms of domestic progress, evantuxumab's application for market approval was accepted by the National Medical Products Administration on October 26, 2023. Meanwhile, Shuvotinib by Daiichi Sankyo obtained official approval on August 22, 2023, as the first domestically developed targeted therapy for EGFRex20ins-mutated NSCLC. It is used as a second-line treatment option.

Evantuxumab, as the pioneering targeted therapy for EGFRex20ins mutations in lung cancer, signifies a significant breakthrough. Its potential to become a first-line treatment option holds promise for the future of lung cancer treatment. The positive clinical results, combined with domestic advancements, highlight the growing importance of evantuxumab in the field of lung cancer therapeutics.